Your browser doesn't support javascript.
loading
Traditional Vietnamese medicine Kovir capsule for non-severe COVID-19 patients: A phase III double-blind randomized controlled trial.
Loc, Huynh Nguyen; Hoan, Vu Minh; Vuong, Nguyen Lam; Lan, Truong Thi Ngoc; Huong, Dinh Thi Lan; Hung, Tran Quoc; Tuyen, Nguyen Thanh; Quang, Tran Minh; Dao, Ly Minh.
Afiliación
  • Loc HN; Traditional Medicine Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Hoan VM; Hanoi General Hospital for Traditional Medicine, Hanoi, Vietnam.
  • Vuong NL; Department of Medical Statistics and Informatics, Faculty of Public Health, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Lan TTN; Traditional Medicine Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Huong DTL; Department of Training, Scientific Researching, Health Activities Direction, Traditional Medicine Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Hung TQ; Hanoi General Hospital for Traditional Medicine, Hanoi, Vietnam.
  • Tuyen NT; Traditional Medicine Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Quang TM; General Medicine Department, Traditional Medicine Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  • Dao LM; Department of Training, Scientific Researching, Health Activities Direction, Traditional Medicine Institute of Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Phytother Res ; 37(6): 2395-2404, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36751127
The number of COVID-19 infections is still increasing with the omicron variant. Although vaccination has shown its effectiveness, efficacious treatments are still required. Kovir, a Vietnamese herbal medicine, has shown potential effects for non-severe COVID-19 patients in terms of symptom resolution and prevention of disease progression in previous studies. This phase-3 trial evaluated the safety and efficacy of Kovir for non-severe COVID-19 adults. Participants were randomized to the Kovir (381 patients) or placebo (192 patients) groups. Outcomes were progression to severe/critical COVID-19, a daily symptom score based on 11 pre-defined symptoms, time to symptom resolution, a negative reverse transcription polymerase chain reaction, an EQ-5D-5L quality of life (QOL) score, and serious adverse events. Only one patient (in the placebo group) progressed to severe COVID-19, thus we could not conclude the effect of Kovir on the prevention of disease progression. Kovir significantly reduced time to symptom resolution (median: 7 vs. 11 days, hazard ratio [95% confidence interval]: 2.03 [1.66-2.48]) compared to placebo. Kovir also increased the QOL score on days 7 and 14. No safety concerns were observed. To conclude, Kovir is safe and facilitates symptom relief for non-severe COVID-19 patients. We advocate using Kovir in the early phase of COVID-19 for non-severe adult patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Phytother Res Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2023 Tipo del documento: Article País de afiliación: Vietnam Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Phytother Res Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2023 Tipo del documento: Article País de afiliación: Vietnam Pais de publicación: Reino Unido